Safety and Performance Assessment of Drug-Eluting Stent CRE8 in Diabetic Patients

UnknownOBSERVATIONAL
Enrollment

1,030

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

February 28, 2022

Study Completion Date

July 31, 2022

Conditions
DiabetesCoronaropathy
Interventions
DEVICE

DES-CRE8

Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.

Trial Locations (22)

19100

Centre Hospitalier Brive, Brive-la-Gaillarde

21000

Hôpital Privé de Bourgogne, Dijon

26000

Centre Hospitalier Valence, Valence

38043

Centre Hospitalier Universitaire Grenoble, Grenoble

49800

Clinique Saint-Joseph, Trélazé

54270

Clinique Pasteur, Essey-lès-Nancy

56017

Centre Hospitalier Vannes, Vannes

60000

Centre Hospitalier Beauvais, Beauvais

64000

Centre Hospitalier Pau, Pau

67500

Centre Hospitalier Haguenau, Haguenau

68003

Hôpital Schweitzer, Colmar

69365

Centre Hospitalier Saint-Joseph Saint-Luc, Lyon

76000

Clinique Saint-Hilaire, Rouen

80090

Clinique de l'Europe, Amiens

82000

Clinique Pont de Chaumes, Montauban

84902

Centre Hospitalier Avignon, Avignon

91106

Centre Hospitalier Sud-Francilien, Corbeil-Essonnes

95500

Centre Hospitalier Gonesse, Gonesse

95602

Hôpital Simone Veil, Eaubonne

280018

Centre Hospitalier Chartres, Chartres

01004

Clinique Convert, Bourg-en-Bresse

02321

Centre Hospitalier Saint-Quentin, Saint-Quentin

All Listed Sponsors
collaborator

EVAMED

OTHER

lead

Alvimedica Medical Technologies France

INDUSTRY

NCT03842813 - Safety and Performance Assessment of Drug-Eluting Stent CRE8 in Diabetic Patients | Biotech Hunter | Biotech Hunter